Prevention of cardiovascular events by treating hypertension in older adults: An evidence-based approach

Journal of Clinical Hypertension

Volumn 10, Issue 3, 2008, Pages 219-225

  Firdaus, Muhammad ^a   Sivaram, Chittur A ^a   Reynolds, Dwight W ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT;

AGED; CAUSE OF DEATH; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG COMBINATION; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL; REVIEW; STROKE;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CAUSE OF DEATH; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM CHLORIDE SYMPORTER INHIBITORS; STROKE;

EID: 43549105881     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2008.07428.x     Document Type: Review

References (51)

1. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
2. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44:398-404.
3. Borzecki AM, Wong AT. Hickey EC, et al. Hypertension control: how well are we doing? Arch Intern Med. 2003;163:2705-2711.
4. Giles TD. Pharmacoeconomic issues in antihypertensive therapy. Am J Cardiol. 1999;84:25K-28K.
5. Hobbs FB, Damon BL. Sixty-five Plus in America. Current Population Reports, Special Studies. Washington, DC: US Department of Commerce, Economics, and Statistics Administration, Bureau of the Census; 1996.
6. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med. 1993;153:598-615.
7. Stokes J 3rd, Kannel WB, Wolf PA, et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham Study-30 years of follow up. Hypertension. 1989;13:I13-I18.
8. van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med. 2000;342:1-8.
9. Martin MJ, Hulley SB, Kuller LH, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet. 1986;2:933-936.
10. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
11. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. Am J Cardiol. 1971;27:335-345.
12. Dustan HP. 50th anniversary historical article. Hypertension. J Am Coll Cardiol. 1999;33:595-597.
13. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation. 1999;100:354-360.
14. Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension. 1994;23:395-401.
15. Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 study. Lancet. 1999;354:1751-1756.
16. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
17. Neal B, MacMahon S, Chapman N; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other bloodpressure- lowering drugs. Lancet. 2000;356:1955-1964.
18. Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomized controlled trials. Lancet. 1999;353:793-796.
19. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49:69-75.
20. Moser M, Franklin SS. Hypertension management: results of a new national survey for the hypertension education foundation: Harris interactive. J Clin Hypertens (Greenwich). 2007;9:316-323.
21. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med. 2001;345:479-486.
22. Hajjar I, Miller K, Hirth V. Age-related bias in the management of hypertension: a national survey of physicians' opinions on hypertension in elderly adults. J Gerontol A Biol Sci Med Sci. 2002;57:M487-M491.
23. Applegate WB. Hypertension in elderly patients. Ann Intern Med. 1989;110:901-915.
24. Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet. 1985;1(8442):1349-1354.
25. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ. 1986;293:1145-1151.
26. Dahlöf B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-HTN). Lancet. 1991;338:1281-1285.
27. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ. 1992;304:405-412.
28. Staessen JA, Fagard R, Thijs L, et al. Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet. 1997;350:757-764.
29. Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension. Systolic hypertension in China (Sys-China) Collaborative Group. J Hypertens. 16:1823-1829.
30. Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic HTN in the elderly: meta-analysis of outcome trials. Lancet. 2000;355(9207):865-872.
31. He J, Whelton PK. Elevated systolic blood pressure as a risk factor for cardiovascular and renal disease. J Hypertens Suppl. 1999;17:S7-S13.
32. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-1351.
33. Forette F, Seux ML, Staessen JA, et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic HTN in Europe (Syst-Eur) study. Arch Intern Med. 2002;162:2046-2052.
34. News and events. Imperial College London. Trial stops after stroke and mortality significantly reduced by blood pressure- lowering treatment for elderly patients. http://www1.ic.ac.uk/medicine/news/p70708/Accessed September 20, 2007.
35. Bulpitt CJ, Fletcher AE. Prognostic significance of blood pressure in the very old. Implications for the treatment decision. Drugs Aging. 1994;5:184-191.
36. Lernfelt B, Svanborg A. Change in blood pressure in the age interval 70-90. Late blood pressure peak related to longer survival. Blood Press. 2002;11:206-212.
37. Amery A, Birkenhager W, Brixko P, et al. Influence of antihypertensive drug treatment on morbidity and mortality in patients over the age of 60 years. European Working Party on High blood pressure in the Elderly (EWPHE) results: sub-group analysis on entry stratification. J Hypertens Suppl. 1986;4(suppl 6):S642-S647.
38. Bulpitt CJ, Fletcher AE, Amery A, et al. The Hypertension in the Very Elderly Trial (HYVET). J Hum Hypertens. 1994;8:631-632.
39. Bulpitt CJ, Fletcher AE, Amery A, et al. The Hypertension in the Very Elderly Trial (HYVET). Drugs Aging. 1994;5:171-183.
40. Bulpitt CJ, Beckett NS, Cooke J, et al. Hypertension in the Very Elderly Trial Working Group. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens. 2003;21:2409-2417.
41. Bowman TS, Sesso HD, Glynn RJ, et al. JNC 7 category and risk of cardiovascular death in men: are there differences by age? Am J Geriatr Cardiol. 2005;14:126-131.
42. Liszka HA, Mainous AG 3rd, King DE, et al. Prehypertension and cardiovascular morbidity. Ann Fam Med. 2005;3:294-299.
43. Mainous AG 3rd, Everett CJ, Liszka H, et al. Prehypertention and mortality in a nationally representative cohort. Am J Cardiol. 2004;94:1496-1500.
44. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277:739-745.
45. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
46. Lindholm LH, Carlberg B, Samuelsson O. Should b-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
47. Fischer MA, Avorn J. Economic Implications of Evidence- Based Prescribing for HTN Can Better Care Cost Less? JAMA. 2004;291:1850-1856.
48. Malacco E, Mancia G, Rappelli A, et al. SH ELL Investigators. Treatment of isolated systolic hypertension: the SHELL study results. Blood Press. 2003;12:160-167.
49. Moser M, Alderman MH, Wright JT Jr. Roundtable discussion: Clinical problems in the management of hypertension 1) Prehypertension: should we treat? 2) The very elderly: how should we treat. J Clin Hypertens (Greenwich). 2004;6:262-266.
50. Healthy People 2010: Understanding and improving Health. 2nd ed. US Department of Health and Human Services. Washington, DC: US Government Printing Office. November 2000.
51. Smaha LA. From bench to bedside: the future is now. Presented at the 72nd Scientific Sessions of the American Heart Association, Atlanta, Georgia. Circulation. 2000;101:942-945.